Timing of meningococcal vaccination with 4CMenB (Bexsero®) in children with invasive meningococcal group B (MenB) disease in England

Shamez N. Ladhani; Helen Campbell; Zahin Amin-Chowdhury; Jay Lucidarme; Ray Borrow; Mary E. Ramsay

doi:10.1016/j.vaccine.2021.12.010

Timing of meningococcal vaccination with 4CMenB (Bexsero®) in children with invasive meningococcal group B (MenB) disease in England

Shamez N. Ladhani^*, Helen Campbell, Zahin Amin-Chowdhury, Jay Lucidarme, Ray Borrow, Mary E. Ramsay

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

4 Citations (Scopus)

Abstract

Background: Timely vaccination is critical for providing early protection against meningococcal B (MenB) disease because of the high incidence in early childhood. We assessed the timeliness of vaccination in children with confirmed MenB disease after 4CMenB (a recombinant protein-based vaccine) implementation into the national infant immunisation programme in England.

Methods: Public Health England (PHE) conducts surveillance of invasive meningococcal disease (IMD) in England. Children born since 01 July 2015 who developed MenB disease between 01 September 2015 and 31 August 2019 (four surveillance years) were included in the analysis.

Results: There were 276 children with laboratory-confirmed MenB disease, including 36 infants who were too young for vaccination, 59 who were eligible for one 4CMenB dose, 104 for two doses and 77 for 3 doses before they developed MenB disease. Prior to developing MenB disease, there were 59 opportunities for vaccination with two 4CMenB doses in 48/104 (46.5%) eligible infants and 41 opportunities in 28/77 (36.6%) children aged ≥ 1 year who were under-immunised. A schedule with a shorter interval at 8 and 12 weeks of age, compared to the current schedule at 8 and 16 weeks, had the potential to offer an additional 4CMenB dose to 35/58 infants (58.6%) who developed MenB disease between 10 and 18 weeks of age. Conclusions: A high proportion of infants and toddlers with laboratory-confirmed MenB disease had not received their scheduled 4CMenB vaccine prior to developing MenB disease. An infant priming schedule with a shorter interval of 4 weeks has the potential to provide earlier protection against MenB disease.

Original language	English
Pages (from-to)	1493-1498
Number of pages	6
Journal	Vaccine
Volume	40
Issue number	10
Early online date	8 Feb 2022
DOIs	https://doi.org/10.1016/j.vaccine.2021.12.010
Publication status	Published - 1 Mar 2022

Bibliographical note

Funding Information: This study did not receive any funding. The authors had sole responsibility for the study design, data collection, data analysis, data interpretation, and writing of the report. The authors are all employed by Public Health England, the study funder, which is a public body, an executive agency of the Department of Health. The corresponding author had full access to all the data in the study and final responsibility for the decision to submit for publication.

Open Access: No Open Access licence.

Publisher Copyright: Crown Copyright © 2021 Published by Elsevier Ltd. All rights reserved.

Citation: Ladhani, Shamez N., et al. "Timing of meningococcal vaccination with 4CMenB (Bexsero®) in children with invasive meningococcal group B (MenB) disease in England." Vaccine 40.10 (2022): 1493-1498.

DOI: https://doi.org/10.1016/j.vaccine.2021.12.010

Keywords

4CMenB
Delayed vaccination
Meningococcal disease
Prevention, meningococcal vaccine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.vaccine.2021.12.010

Cite this

@article{e2162280893c4f13bfa6ecf43e64b873,

title = "Timing of meningococcal vaccination with 4CMenB (Bexsero{\textregistered}) in children with invasive meningococcal group B (MenB) disease in England",

abstract = "Background: Timely vaccination is critical for providing early protection against meningococcal B (MenB) disease because of the high incidence in early childhood. We assessed the timeliness of vaccination in children with confirmed MenB disease after 4CMenB (a recombinant protein-based vaccine) implementation into the national infant immunisation programme in England. Methods: Public Health England (PHE) conducts surveillance of invasive meningococcal disease (IMD) in England. Children born since 01 July 2015 who developed MenB disease between 01 September 2015 and 31 August 2019 (four surveillance years) were included in the analysis. Results: There were 276 children with laboratory-confirmed MenB disease, including 36 infants who were too young for vaccination, 59 who were eligible for one 4CMenB dose, 104 for two doses and 77 for 3 doses before they developed MenB disease. Prior to developing MenB disease, there were 59 opportunities for vaccination with two 4CMenB doses in 48/104 (46.5%) eligible infants and 41 opportunities in 28/77 (36.6%) children aged ≥ 1 year who were under-immunised. A schedule with a shorter interval at 8 and 12 weeks of age, compared to the current schedule at 8 and 16 weeks, had the potential to offer an additional 4CMenB dose to 35/58 infants (58.6%) who developed MenB disease between 10 and 18 weeks of age. Conclusions: A high proportion of infants and toddlers with laboratory-confirmed MenB disease had not received their scheduled 4CMenB vaccine prior to developing MenB disease. An infant priming schedule with a shorter interval of 4 weeks has the potential to provide earlier protection against MenB disease.",

keywords = "4CMenB, Delayed vaccination, Meningococcal disease, Prevention, meningococcal vaccine",

author = "Ladhani, {Shamez N.} and Helen Campbell and Zahin Amin-Chowdhury and Jay Lucidarme and Ray Borrow and Ramsay, {Mary E.}",

note = "Funding Information: This study did not receive any funding. The authors had sole responsibility for the study design, data collection, data analysis, data interpretation, and writing of the report. The authors are all employed by Public Health England, the study funder, which is a public body, an executive agency of the Department of Health. The corresponding author had full access to all the data in the study and final responsibility for the decision to submit for publication. Open Access: No Open Access licence. Publisher Copyright: Crown Copyright {\textcopyright} 2021 Published by Elsevier Ltd. All rights reserved. Citation: Ladhani, Shamez N., et al. {"}Timing of meningococcal vaccination with 4CMenB (Bexsero{\textregistered}) in children with invasive meningococcal group B (MenB) disease in England.{"} Vaccine 40.10 (2022): 1493-1498. DOI: https://doi.org/10.1016/j.vaccine.2021.12.010",

year = "2022",

month = mar,

day = "1",

doi = "10.1016/j.vaccine.2021.12.010",

language = "English",

volume = "40",

pages = "1493--1498",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier",

number = "10",

}

TY - JOUR

T1 - Timing of meningococcal vaccination with 4CMenB (Bexsero®) in children with invasive meningococcal group B (MenB) disease in England

AU - Ladhani, Shamez N.

AU - Campbell, Helen

AU - Amin-Chowdhury, Zahin

AU - Lucidarme, Jay

AU - Borrow, Ray

AU - Ramsay, Mary E.

N1 - Funding Information: This study did not receive any funding. The authors had sole responsibility for the study design, data collection, data analysis, data interpretation, and writing of the report. The authors are all employed by Public Health England, the study funder, which is a public body, an executive agency of the Department of Health. The corresponding author had full access to all the data in the study and final responsibility for the decision to submit for publication. Open Access: No Open Access licence. Publisher Copyright: Crown Copyright © 2021 Published by Elsevier Ltd. All rights reserved. Citation: Ladhani, Shamez N., et al. "Timing of meningococcal vaccination with 4CMenB (Bexsero®) in children with invasive meningococcal group B (MenB) disease in England." Vaccine 40.10 (2022): 1493-1498. DOI: https://doi.org/10.1016/j.vaccine.2021.12.010

PY - 2022/3/1

Y1 - 2022/3/1

N2 - Background: Timely vaccination is critical for providing early protection against meningococcal B (MenB) disease because of the high incidence in early childhood. We assessed the timeliness of vaccination in children with confirmed MenB disease after 4CMenB (a recombinant protein-based vaccine) implementation into the national infant immunisation programme in England. Methods: Public Health England (PHE) conducts surveillance of invasive meningococcal disease (IMD) in England. Children born since 01 July 2015 who developed MenB disease between 01 September 2015 and 31 August 2019 (four surveillance years) were included in the analysis. Results: There were 276 children with laboratory-confirmed MenB disease, including 36 infants who were too young for vaccination, 59 who were eligible for one 4CMenB dose, 104 for two doses and 77 for 3 doses before they developed MenB disease. Prior to developing MenB disease, there were 59 opportunities for vaccination with two 4CMenB doses in 48/104 (46.5%) eligible infants and 41 opportunities in 28/77 (36.6%) children aged ≥ 1 year who were under-immunised. A schedule with a shorter interval at 8 and 12 weeks of age, compared to the current schedule at 8 and 16 weeks, had the potential to offer an additional 4CMenB dose to 35/58 infants (58.6%) who developed MenB disease between 10 and 18 weeks of age. Conclusions: A high proportion of infants and toddlers with laboratory-confirmed MenB disease had not received their scheduled 4CMenB vaccine prior to developing MenB disease. An infant priming schedule with a shorter interval of 4 weeks has the potential to provide earlier protection against MenB disease.

AB - Background: Timely vaccination is critical for providing early protection against meningococcal B (MenB) disease because of the high incidence in early childhood. We assessed the timeliness of vaccination in children with confirmed MenB disease after 4CMenB (a recombinant protein-based vaccine) implementation into the national infant immunisation programme in England. Methods: Public Health England (PHE) conducts surveillance of invasive meningococcal disease (IMD) in England. Children born since 01 July 2015 who developed MenB disease between 01 September 2015 and 31 August 2019 (four surveillance years) were included in the analysis. Results: There were 276 children with laboratory-confirmed MenB disease, including 36 infants who were too young for vaccination, 59 who were eligible for one 4CMenB dose, 104 for two doses and 77 for 3 doses before they developed MenB disease. Prior to developing MenB disease, there were 59 opportunities for vaccination with two 4CMenB doses in 48/104 (46.5%) eligible infants and 41 opportunities in 28/77 (36.6%) children aged ≥ 1 year who were under-immunised. A schedule with a shorter interval at 8 and 12 weeks of age, compared to the current schedule at 8 and 16 weeks, had the potential to offer an additional 4CMenB dose to 35/58 infants (58.6%) who developed MenB disease between 10 and 18 weeks of age. Conclusions: A high proportion of infants and toddlers with laboratory-confirmed MenB disease had not received their scheduled 4CMenB vaccine prior to developing MenB disease. An infant priming schedule with a shorter interval of 4 weeks has the potential to provide earlier protection against MenB disease.

KW - 4CMenB

KW - Delayed vaccination

KW - Meningococcal disease

KW - Prevention, meningococcal vaccine

UR - http://www.scopus.com/inward/record.url?scp=85124320628&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2021.12.010

DO - 10.1016/j.vaccine.2021.12.010

M3 - Article

AN - SCOPUS:85124320628

SN - 0264-410X

VL - 40

SP - 1493

EP - 1498

JO - Vaccine

JF - Vaccine

IS - 10

ER -

Timing of meningococcal vaccination with 4CMenB (Bexsero®) in children with invasive meningococcal group B (MenB) disease in England

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this